Effectiveness of ciprofloxacin or linezolid in combination with rifampicin against Enterococcus faecalis in biofilms

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 2, 2012, Pages 433-439

  Holmberg, Anna ^a   Mörgelin, Matthias ^a   Rasmussen, Magnus ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Antibiotic resistance; Bacterial biofilm; MBEC; Prosthetic joint infections

Indexed keywords

AMPICILLIN; BONE CEMENT; CIPROFLOXACIN; LINEZOLID; RIFAMPICIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; BIOFILM; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; ENTEROCOCCUS FAECALIS; ERADICATION THERAPY; HIP PROSTHESIS; IN VITRO STUDY; KNEE PROSTHESIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROSTHESIS INFECTION;

ACETAMIDES; ANTI-BACTERIAL AGENTS; BIOFILMS; CIPROFLOXACIN; COLONY COUNT, MICROBIAL; ENTEROCOCCUS FAECALIS; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; OXAZOLIDINONES; RIFAMPIN;

EID: 84855822708     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr477     Document Type: Article

References (40)

1. Anguita-Alonso P, Hanssen AD, Patel R. Prosthetic joint infection. Expert Rev Anti Infect Ther 2005; 3: 797-804.
2. Philips JE, Crane TP. The incidence of deep prosthetic infections in a specialist orthopaedic hospital: a 15 -year prospective survey. J Bone Joint Surg Br 2006; 88: 943-8.
3. Stefánsdóttir A, Johansson D, Knutson K et al. Microbiology of the infected knee arthroplasty: report from the Swedish Knee Arthroplasty Register on 426 surgically revised cases. Scand J Infect Dis 2009; 41: 831-40.
4. Lavernia C, Lee DJ, Hernandez VH. The increasing financial burden of knee revision surgery in the United States. Clin Orthop Relat Res 2006; 446: 221-6.
5. Kurtz SM, Ong KL, Schmier J et al. Future clinical and economic impact of revision total hip and knee arthroplasty. J Bone Joint Surg Am 2007; 89 Suppl 3: 144-51.
6. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15: 167-93.
7. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2004; 2: 95-108.
8. Lewis K. Riddle of biofilm resistance. Antimicrob Agents Chemother 2001; 45: 999-1007.
9. Costerton JW, Stewart PS. Battling biofilms. Sci Am 2001; 285: 74-81.
10. Costerton JW, Montanaro L, Arciola CR. Biofilm in implant infections: its production and regulation. Int J Artif Organs 2005; 28: 1062-8.
11. Davies D. Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov 2003; 2: 114-22.
12. Hall-Stoodley L, Stoodley P. Evolving concepts in biofilm infections. Cell Microbiol 2009; 11: 1034-43.
13. Mah TF, O'Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 2001; 9: 34-9.
14. Sandoe JA, Wysome J, West AP et al. Measurement of ampicillin, vancomycin, linezolid and gentamicin activity against enterococcal biofilms. J Antimicrob Chemother 2006; 57: 767-70.
15. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004; 351: 1645-54.
16. Trampuz A, Widmer AF. Infections associated with orthopedic implants. Curr Opin Infect Dis 2006; 19: 349-56.
17. Trampuz A, Zimmerli W. Prosthetic joint infections: update in diagnosis and treatment. Swiss Med Wkly 2005; 135: 243-51.
18. Zimmerli W, Widmer AF, Blatter M et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998; 279: 1537-41.
19. Zavasky DM, Sande MA. Reconsideration of rifampin: a unique drug for a unique infection. JAMA 1998; 279: 1575-7.
20. Zimmerli W, Frei R, Widmer AF et al. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J Antimicrob Chemother 1994; 33: 959-67.
21. Drancourt M, Stein A, Argenson JN et al. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother 1997; 39: 235-40.
22. Baldoni D, Haschke M, Rajacic Z et al. Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection. Antimicrob Agents Chemother 2009; 53: 1142-8.
23. Blaser J, Vergères P, Widmer AF et al. In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob Agents Chemother 1995; 39: 1134-9.
24. El Helou OC, Berbari EF, Marculescu CE et al. Outcome of enterococcal prosthetic joint infection: is combination systemic therapy superior to monotherapy? Clin Infect Dis 2008; 47: 903-9.
25. Sandoe JA, Witherden IR, Cove JH et al. Correlation between enterococcal biofilm formation in vitro and medical-device-related infection potential in vivo. J Med Microbiol 2003; 52: 547-50.
26. Euba G, Lora-Tamayo J, Murillo O et al. Pilot study of ampicillin-ceftriaxone combination for treatment of orthopedic infections due to Enterococcus faecalis. Antimicrob Agents Chemother 2009; 53: 4305-10.
27. Ceri H, Olson ME, Stremick C et al. The Calgary Biofilm Device: new technology for rapid determation of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999; 37: 1771-6.
28. Holmberg A, Lood R, Mörgelin M et al. Biofilm formation by Propionibacterium acnes is a characteristic of invasive isolates. Clin Microbiol Infect 2009; 15: 787-95.
29. Weismeier K, Adam D, Heilmann HD et al. Penetration of amoxycillin/ clavulanate into human bone. J Antimicrob Chemother 1989; 24: 93-100.
30. Graziani AL, Lawson LA, Gibson GA et al. Vancomycin concentrations in infected and noninfected human bone. Antimicrob Agents Chemother 1988; 32: 1320-2.
31. Rana B, Butcher I, Grigoris P et al. Linezolid penetration into osteo-articular tissues. J Antimicrob Chemother 2002; 50: 747-50.
32. Bosseray A, Leclercq P, Manguat G et al. Penetration of ciprofloxacin into synovial fluid after oral dosing. J Antimicrob Chemother 1992; 30: 74-5.
33. Roth B. Penetration of parenterally administered rifampicin into bone tissue. Chemotherapy 1984; 30: 358-65.
34. Moellering RC Jr. The Garrod Lecture. The enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options. J Antimicrob Chemother 1991; 28: 1-12.
35. Mohamed JA, Huang DB. Biofilm formation by enterococci. J Med Microbiol 2007; 56: 1581-8.
36. Aubry-Damon HS, Soussy C-J, Courvalin P. Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1998; 42: 2590-4.
37. Rose WE, Poppens PT. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. J Antimicrob Chemother 2009; 63: 485-8.
38. Vogler AJ, Busch JD, Percy-Fine S et al. Molecular analysis of rifampin resistance in Bacillus anthracis and Bacillus cereus. Antimicrob Agents Chemother 2002; 46: 511-3.
39. Santoro CM, Bush K, Abbanat D. Characterisation of Staphylococcus aureus and Enterococcus faecalis mutants with reduced susceptibility to the investigational oxazolidinone RWJ-416457. Int J Antimicrob Agents 2010; 36: 424-9.
40. Spiliopoulou I, Damani A, Chini V et al. Linezolid-resistant enterococci in Greece: epidemiological characteristics. Chemotherapy 2011; 57: 181-5.